Significance of Cyclooxygenase‑2, Prostaglandin E2 and CD133 Levels in Sunitinib‑resistant Renal Cell Carcinoma

Oncology Letters - Greece
doi 10.3892/ol.2019.10442
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Arachidonic Acid Is Preferentially Metabolized by Cyclooxygenase-2 to Prostacyclin and Prostaglandin E2

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Cyclooxygenase-2 (COX-2); Prostaglandin E2 (PGE2); VEGF Receptor 2 (KDR/Flk-1; VEGFR-2)

Science-Business eXchange
2014English

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2016English

A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology
Urology
2012English

Cox-2 Inhibition Enhances the Activity of Sunitinib in Human Renal Cell Carcinoma Xenografts

British Journal of Cancer
Cancer ResearchOncology
2013English

Mp92-07 Netrin-1: A Novel Protein Identified in Disease Progression of Sunitinib Resistant Renal Cell Carcinoma

Journal of Urology
Urology
2016English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy

New England Journal of Medicine
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy